New hope for hard-to-treat head and neck cancer: combo therapy aims to shrink tumors
NCT ID NCT07529873
First seen Apr 20, 2026 · Last updated May 09, 2026 · Updated 5 times
Summary
This study tests whether adding a new drug (ficerafusp alfa) to an existing immunotherapy (nivolumab) can shrink tumors better than nivolumab alone in people with advanced head and neck cancer that stopped responding to platinum chemotherapy. About 131 adults aged 18-75 will participate. The goal is to control the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SCCHN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.